Stock EVT EVOTEC SE
Add to a list
To use this feature you must be a member
Log inSign up

News Evotec SE

Equities

EVT

DE0005664809

Market Closed - Xetra
Other stock markets
 11:35:17 2024-04-23 am EDT 		After market 12:24:28 pm
14.18 EUR +3.50% Intraday chart for Evotec SE 14.16 -0.14%
Apr. 18 Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis MT
Apr. 18 Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis
MT
Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis
MT
Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
EQ
Evotec SE to announce results for fiscal year 2023 on 24 April 2024
EQ
Evotec Names First Chief People Officer
MT
Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024
CI
Evotec welcomes Aurélie Dalbiez as Chief People Officer
EQ
AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQ
AFR: Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
Deutsche Bank raises Evotec to 'Buy' - Frustration after CEO departure overcome
DP
STOXX 600 climbs over 1% on rate-cut optimism
RE
Deutsche Bank Research raises Evotec to 'Buy' - Target 19 Euro
DP
EVOTEC : Deutsche Bank takes a positive view
ZD
U.S. Futures, European Stocks Up as ECB Signals Moving Closer to Rate Cut
DJ
Evotec : Company Presentatio
PU
Evotec : Unternehmenspräsentation(englisch
PU
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
EVOTEC : Receives a Buy rating from Jefferies
ZD
Aeovian Pharmaceuticals, Inc. announced that it has received $87 million in funding from Sofinnova Investment, Inc., Evotec SE, venBio LLC, Apollo Health Ventures, b2venture AG, Hevolution Foundation
CI
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE